BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11731409)

  • 1. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals.
    Vonderheide RH; Schultze JL; Anderson KS; Maecker B; Butler MO; Xia Z; Kuroda MJ; von Bergwelt-Baildon MS; Bedor MM; Hoar KM; Schnipper DR; Brooks MW; Letvin NL; Stephans KF; Wucherpfennig KW; Hahn WC; Nadler LM
    Cancer Res; 2001 Dec; 61(23):8366-70. PubMed ID: 11731409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
    Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
    Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
    Dupont J; Latouche JB; Ma C; Sadelain M
    Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic T-cell immunity against telomerase reverse transcriptase in colorectal cancer patients.
    Titu LV; Loveday RL; Madden LA; Cawkwell L; Monson JR; Greenman J
    Oncol Rep; 2004 Oct; 12(4):871-6. PubMed ID: 15375515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
    Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
    Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.
    Schroers R; Huang XF; Hammer J; Zhang J; Chen SY
    Cancer Res; 2002 May; 62(9):2600-5. PubMed ID: 11980655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer.
    Amarnath SM; Dyer CE; Ramesh A; Iwuagwu O; Drew PJ; Greenman J
    Int J Oncol; 2004 Jul; 25(1):211-7. PubMed ID: 15202008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunogenicity of the hTERT540-548 peptide in cancer.
    Wenandy L; Sørensen RB; Sengeløv L; Svane IM; thor Straten P; Andersen MH
    Clin Cancer Res; 2008 Jan; 14(1):4-7. PubMed ID: 18172245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
    Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
    Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
    Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
    Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
    Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
    Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uses of telomerase peptides in anti-tumor immune therapy.
    Li H; Katik I; Liu JP
    Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
    Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
    Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Human telomerase reverse transcriptase as a novel target for tumor immunotherapy].
    Pang JX
    Ai Zheng; 2003 Aug; 22(8):893-5. PubMed ID: 12917043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
    Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
    Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells.
    Kryukov F; Ocadlíková D; Kovárová L; Buresová I; Hájek R; Michálek J
    J Immunotoxicol; 2009 Dec; 6(4):243-8. PubMed ID: 19908943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
    Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
    Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors.
    Frolkis M; Fischer MB; Wang Z; Lebkowski JS; Chiu CP; Majumdar AS
    Cancer Gene Ther; 2003 Mar; 10(3):239-49. PubMed ID: 12637945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.